THE USE OF A COMMERCIALLY AVAILABLE IMMUNOASSAY TO DETERMINE THE LEVEL OF INTERLEUKIN-6 IN THE SERUM OF PATIENTS WITH MYELOMA

被引：16

作者：

BROWN, R

JOSHUA, D

UHR, E

SNOWDON, L

GIBSON, J

机构：

[1] Haematology Department, Royal Prince Alfred Hospital, Sydney

来源：

LEUKEMIA & LYMPHOMA | 1991年 / 5卷 / 2-3期

关键词：

INTERLEUKIN-6; MYELOMA; IMMUNOASSAY;

D O I：

10.3109/10428199109068119

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Interleukin-6 (IL-6) is the B cell growth factor which stimulates the final differentiation of B cells to plasma cells and has been suggested to be an autocrine growth factor in patients with multiple myeloma. We have compared the concentration of IL-6 in the serum of patients with myeloma at diagnosis (n = 11), in plateau phase (n = 10) and with progressive disease (n = 13) using Intertest-6, a commercially available enzyme-linked immunoassay (ELISA). Longitudinal studies were performed with 6 patients. IL-6 levels were normal in all myeloma sera studied and did not change with disease progression. Serum IL-6 levels did not correlate with disease activity as determined by serum thymidine kinase (r = 0.07) nor did serum IL-6 provide any useful prognostic data. These results contradict previous studies using bioassays which reported that IL-6 levels increase significantly during progressive disease. Until this problem is resolved and these assays are validated, studies which attempt to quantitate IL-6 and other growth factors in serum should be treated with some caution. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：151 / 155

页数：5

共 28 条

[1]

Dutton R.W., Falkoff R., Hirst J.A., Hoffman M., Kappler J., Kettman J.R., Lesley J.F., Van D., Is there evidence for a nonantigen specific diffusible chemical mediator from the thymus cell in the initiation of the immune response?, Progress in Immunology, 1, pp. 355-370, (1971)

[2]

Kishimoto T., Ishizaka K., Regulation of antibody responses in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response, Journal of Immunology, 111, pp. 1194-1205, (1973)

[3]

Muraguchi A., Kishimoto T., Miki Y., Kuritani T., Kaieda T., Yoshizaki K., Yamamura Y., T cell replacing factor (TRF)-induced IgG secretion in human B blastoid cell line and demonstration of acceptors for TRF, Journal of Immunology, 127, pp. 412-416, (1981)

[4]

Okada M., Sakaguchi N., Yoshimura N., Hara H., Shimizu K., Yoshida N., Yoshizaki K., Kishimoto S., Yamamura Y., Kishimoto T., B-cell growth factor (BCGF) and B cell differentiation factor from human T hybridomas: Two distinct kinds of BCGFs and their synergism in B cell proliferation, Journal of Experimental Medicine, 157, pp. 583-590, (1989)

[5]

Kishimoto T., The biology of Interleukin-6, Blood, 74, pp. 1-10, (1989)

[6]

Harada N., Kikuchi Y., Taminaga A., Takaki S., Takatsu K., BCGF II activity on activated B cells of a purified murine T cell replacing factor (TRF) from a T cell hybridoma (B151K12), Journal of Immunology, 134, pp. 3944-3951, (1985)

[7]

Kinashi T., Harada N., Severinson E., Tanabe R., Sideras P., Konishi M., Azuma C., Tominaga A., Bergstedt-Lindquist S., Takahashi M., Matsuda F., Yaoita Y., Takatsu K., Honjo T., Cloning of complementary DNA coding T-cell replacing factor and identity with B-cell growth factor II, Nature, 324, pp. 70-73, (1986)

[8]

Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F., Interleukin 3 and Interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma, Journal of Experimental Medicine, 170, pp. 613-618, (1989)

[9]

Van Damme J.G., Opdenakker G., Simpson R.J., Rubira M.R., Cayphas S., Vink A., Billau A., Van Snick J., Identification of the human 26kD protein, interferon B2 (IFN-B2) as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor, Journal of Experimental Medicine, 165, pp. 914-920, (1987)

[10]

Asaoku H., Kawano M., Iwato K., Tanabe O., Tanaka H., Hirano T., Kishimoto T., Kuramoto A., Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma, Blood, 72, pp. 429-432, (1988)

← 1 2 3 →